US pharmaceutical company Eli Lilly reports positive 52-week results from the phase 3b Together-PsA study, in which the combination of Taltz and Zepbound showed greater efficacy than Taltz alone in patients with psoriatic arthritis and overweight or obesity. This is stated in a press release.
After one year, 43.7 percent of the patients receiving the combination treatment had achieved at least a 50 percent reduction in disease activity, compared with 15.7 percent for Taltz alone. The treatment also resulted in improvements in weight, blood pressure and blood glucose levels, among other things.
The results were presented at the rheumatology congress ACR Convergence 2026 and published simultaneously in the journal Arthritis & Rheumatology.
